Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Senior US exec joins Aus firm

Posted 23 February 2021 AM

An Australian company that is using real world evidence to back regulatory filings for a new cannabinoid medicine designed to reduce symptoms of anxiety, depression and stress has appointed a senior US pharma executive to lead its Strategic Advisory Board.

Dr Karen Smith, who has served as chief medical officer for Jazz Pharmaceuticals among other roles will chair the board for ASX-listed Emyria.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Approvals Action
Pfizer vs Humira
Adds to a growing list of adalimumab biosims
Top of the Hill
How not to reform the PBAC
In the face of deep change, is piecemeal enough?
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas